Just days after their laboratories were damaged in the Iranian attack of the Weizmann Institute of Science, Professors Liran Shlush and Amos Tanay today publish a study expected to advance the field of blood cell medicine. What if a blood test could reveal the pace of...
Researchers from Professor Yardena Samuels’s lab at the Weizmann Institute of Science have manipulated cancer cells into making themselves visible to the immune system, creating a new approach that gives hope to patients with previously untreatable disease. When your...
A newly developed antibody-based treatment for the most aggressive type of breast cancer could also be used to treat many other cancers new Weizmann Institute of Science research shows. “Build your enemy a golden bridge to retreat across” is a piece of advice said by...
A new Weizmann Institute of Science approach promises to advance cancer immunotherapy by increasing the proliferation rate of cancer-targeting immune cells while retaining their ability to kill cancer cells. Cellular immunotherapy, a leading form of cancer treatment,...
Weizmann Insitute scientists have mapped common types of brain tumours at unprecedented resolution – and identified a possible reason why some patients fail to respond to a new drug. The cells that make up cancerous brain tumours are extremely varied and sometimes...
A new cellular mechanism for identifying unravelled proteins, discovered by scientists at the Weizmann Institute of Science and recently published in Molecular Cell, may serve as a target for cancer therapies. “Who will watch the watchers?” asked Roman poet Juvenal...
Altered glucose digested by cancer cells helps reveal tumours’ hiding places, new research at the Weizmann Insitute of Science shows. Pancreatic cancer is difficult to detect, in part because the pancreas sits deep in the abdominal cavity in a position that can vary...
A new kind of immunotherapy, based on crosstalk between different immune cells, could pave the way for innovative treatments of cancer and autoimmune diseases Winning on the battlefield takes a combination of precise intelligence and resolute soldiers. But when it...
Researchers at the Weizmann Institute of Science have identified a biomarker that may one day enable a subgroup of lung cancer patients to benefit from relapse-free treatment. Non-smokers who develop lung cancer can be treated effectively with new drugs, but their...
Sometimes anticancer antibodies press on the gas and the brakes at the same time. New research from the Weizmann Institute of Research in Israel might help them accelerate better. When driving, putting a foot on the gas or brake pedal controls the car’s speed. This...
We are used to thinking of the immune system as a separate entity, almost a distinct organ, but the truth is much more complicated. Breakthroughs in recent years – some resulting from research performed in Professor Rotem Sorek’s lab at the Weizmann Institute of...
Cancer tumours contain multiple species of fungi that differ per tumour type, according to a large study led by researchers at the Weizmann Institute of Science and the University of California, San Diego. The study, published today in Cell, potentially has...
Blood tests – simple, noninvasive and economically feasible – promise to become the next major milestone in cancer diagnosis. However, most of these tests, dubbed liquid biopsies, are currently not reliable enough for widespread use. A new, multi-parameter approach...
Immunotherapies for cancer rely on recruiting the patient’s immune system, but they still fall far short of tapping into the entire arsenal of the body’s natural defences. In fact, most such therapies draw on one type of immune defines: the ability of T cells to...
New research that reveals the details of an alternative cell death may lead to new therapies for a variety of diseases. Unlikely causes of death, like lightning, may strike out of the blue, but for our cells even an unusual form of death is not left to chance. That’s...
Multiple myeloma patients live much longer today than in the past, thanks to new targeted anti-myeloma drugs, but ultimately most develop resistance to the medications, and in some the disease is resistant to therapy from the start. Weizmann Institute of Science...
A study of melanoma cells explains a puzzling response they exhibit to ward off T cell attacks. Cancers like melanoma are hard to treat, not least because they have a varied bag of tricks for defeating or evading treatments. A combined research effort by scientists...
A new technology developed at the Weizmann Institute of Science may help answer outstanding questions about the immune system, cancer, Alzheimer’s, and more. Invading cells’ private space – prying into their internal functions, decisions and communications – could be...
Choosing the right drug for each cancer patient is key to successful treatment, but currently physicians have few reliable pointers to guide them in designing treatment protocols. Researchers at the Weizmann Institute of Science and Broad Institute of MIT and Harvard...
One of the frustrations with anti-cancer therapy is that no one drug fits all: Most work well in some people but have little effect in other patients with the same type of cancer. This is as true of the newer immunotherapy treatments as it is of older types of...
New Weizmann Institute of Science research shows heterogeneity in melanoma tumours prevents effective immune responses. Diversity – at least among cancer cells – is not a good thing. Weizmann research shows that in melanoma, tumours with cells that have differentiated...
A cancer research project conducted recently at the Weizmann Institute of Science evokes an unusual image: hippos. The research is not about the weighty, mud-basking mammals, but about the ‘Hippo pathway’, a chain of biochemical reactions that, when disrupted, can...
In collaboration with scientists at the Weizmann Institute of Science, privately owned company Steba Biotech conducted extensive research and development on the prostate cancer drug TOOKAD®, which has now received marketing authorisation to make it available in 31...
New collaborative research from the Weizmann Institute of Science has asked a different question about the bacteria in our microbiomes, and the answers, recently published in Nature, could help target disease more precisely. Our gut microbiome – the complement of...